Perbak Capital Partners’s 10x Genomics TXG Stock Holding History

Perbak Capital Partners’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,538	Closed	-$542K	–	237
2026 Q1	$542K	Buy	25,538 +14,371	+129%	+$287K	0.13%	176
2025 Q4	$182K	Buy	+11,167	New	+$169K	0.06%	218
2025 Q2	–	Sell	-35,044	Closed	-$306K	–	334
2025 Q1	$306K	Buy	+35,044	New	+$442K	0.23%	127

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perbak Capital Partners's TXG Position: Q2 2026 in Review

Perbak Capital Partners sold out of 10x Genomics (TXG) in Q2 2026, closing a stake of 25,538 shares — an estimated $542K sold.

Perbak Capital Partners first reported a position in TXG in Q1 2025 and held it in 3 quarters. The position peaked at $542K in Q1 2026. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Perbak Capital Partners reported no remaining 10x Genomics position as of Q2 2026 after selling out during the quarter.
Perbak Capital Partners sold 25,538 10x Genomics shares in Q2 2026, an estimated $542K.
Perbak Capital Partners first reported a position in 10x Genomics in Q1 2025 and held it in 3 quarters.
Perbak Capital Partners's 10x Genomics position peaked at $542K in Q1 2026.
390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Perbak Capital Partners's 13F filing for Q2 2026.